Latest Conference Articles

Lindsay Kroener, MD, offers an overview of current fertility preservation options for patients about to undergo cancer therapy.

Patients with HER2-negative, locally advanced or metastatic breast cancer have experienced improved survival rates both in real-world data and the phase 3 EMBRACA trial.

Frontline treatment with poziotinib yielded promising overall response rates in patients with non–small cell lung cancer and HER2 exon 20 insertion mutations.

Ahead of his presentation at the 39th Annual Miami Breast Cancer Conference, Charles L. Loprinzi, MD, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer.

At a presentation during the 39th Annual Miami Breast Cancer Conference, Lindsay Kroener, MD, highlighted key components related to fertility preservation for patients with breast cancer.

Real-world findings presented at the 39th Annual Miami Breast Cancer Conference showed that eribulin may be an effective agent for previously treated patients with metastatic breast cancer.

The nurse-specific track returns to the Miami Breast Cancer Conference® agenda for a second year in 2022.

Preliminary findings suggest that enfortumab vedotin may be an effective treatment option for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Adjuvant mitotane did not yield a significantly reduced risk of recurrence among patients with adrenocortical carcinoma.

The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.

Cabozantinib is determined to be a safe treatment option for patients with metastatic renal cell carcinoma whose disease failed to respond to prior immunotherapy combinations.

Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.

Adding sacituzumab govitecan to second-line pembrolizumab garnered promising antitumor activity among patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

Nivolumab plus cabozantinib outperformed sunitinib in maintaining health-related quality of life in patients with advanced renal cell carcinoma.

A post-hoc analysis of 2 studies revealed that patients with advanced prostate cancer receiving apalutamide reported positive wellbeing scores during treatment.

The androgen receptor inhibitor darolutamide prolonged overall survival compared with placebo in patients with at least 6 comorbidities.

Frontline niraparib, abiraterone acetate, and prednisone yielded improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

First-line treatment with olaparib plus abiraterone resulted in a 34% risk reduction of radiographic disease progression or death in patients with metastatic castration-resistant prostate cancer.

Combination therapy, selective estrogen receptor degraders, and more were covered at the 2021 San Antonio Breast Cancer Symposium.

Oral Bruton tyrosine kinase inhibitors make notable strides in CLL treatment. Chimeric antigen receptor T-cell therapy continues to command attention by besting standard-of-care therapies.

The oral targeted therapy was linked with maintained appetite, eating habits, and physical function in patients with IDH1-mutated cholangiocarcinoma.

An expert with Stanford Health comments on the potential value of secondary cytoreductive surgery for patients with recurrent ovarian cancer and the need for careful patient selection when considering this treatment strategy.

An expert from the University of California Los Angeles (UCLA) discusses the alarming rate of high-risk uterine cancers among Black women and how researchers are investigating the underlying risk factors at play.

An expert from the University of Colorado (UC Health) comments on ongoing clinical trials which promise to shake up the treatment paradigm of endometrial cancer.

An expert from the Ohio State University Comprehensive Cancer Center discusses whether predictive biomarkers hold the potential to change endometrial prognoses.

Encouraging response rates were observed among patients with BRAF V600E–mutant metastatic colorectal cancer who received a triplet regimen of nivolumab, encorafenib, and cetuximab.

In a 12-month follow-up, the experimental regimen continued to provide clinical benefit to patients with esophageal cancer without compromising quality of life or exhibiting an unmanageable safety profile.

Patients with HER2-positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma experienced a 40% reduced risk of mortality with fam-trastuzumab deruxtecan-nxki, compared with patients who received standard therapy.

Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.

The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events (AEs) in patients with advanced gastric cancer.